Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a beta-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Tau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564 · cited 1×
“Based on this evidence, three lines of transgenic mice expressing human tau have been produced (Brion et al., 1999; Gotz et al., 1995; Ishihara et al., 1999).”
BackgroundProline-directed and non-proline-directed phosphorylation of PHF-tau
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., & Ihara, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.823 · Cited by 557
Tau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495
Tau Mutations Cause Frontotemporal Dementias
Goedert, M., Crowther, R. A., & Spillantini, M. G. (1998) · Neuron · doi:10.1016/s0896-6273(00)80615-7 · Cited by 268
Cited by
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
“[ 48–50].”
Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09340.2002 · Cited by 751
Obeid, R., & Herrmann, W. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.088 · Cited by 490
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J.-Z., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 398
GSK-3 is essential in the pathogenesis of Alzheimer's disease
Takashima, A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s335 · Cited by 396
Self-citationCharacterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease
Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., Ward, S., Reyes, J. F., Philibert, K., Glucksman, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237974 · Cited by 357
Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations
Alonso, A. D. C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405131200 · Cited by 329
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314
“…neurodegeneration (Reed et al., 2001), studies in animal models have shown that overexpression of tau can lead to cell death (Lee et al., 2001; Tanemura et al., 2001, 2002; Tatebayashi et al., 2002) and exhibit behavioral abnormalities and synaptic dysfunction without the presence of NFTs…”
BackgroundIncreased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease
Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., & Takashima, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.11.009 · Cited by 301
“Indeed, the overexpression of tau in various animal models has been shown to induce neurodegeneration (Lee et al., 2001; Tanemura et al., 2001, 2002; Tatebayashi et al., 2002).”
BackgroundSelf-citationA decade of modeling Alzheimer's disease in transgenic mice
MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287
Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability
Alonso, A. D., Cohen, L. S., Corbo, C., Morozova, V., ElIdrissi, A., Phillips, G., & Kleiman, F. E. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00338 · Cited by 278
Götz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274
Tatebayashi, Y., Miyasaka, T., Chui, D.-H., Akagi, T., Mishima, K.-I., Iwasaki, K., Fujiwara, M., Tanemura, K., Murayama, M., Ishiguro, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202205599 · Cited by 272
Self-citationPathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190
Kitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178
“The generation of the tau transgenic mice harboring various FTDP-17 mutations also exhibit NFT-like pathology, neuronal and synaptic loss and cognitive impairments in an age-dependent manner [100-104].”
BackgroundKimura, T., Yamashita, S., Fukuda, T., Park, J., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., & Takashima, A. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601917 · Cited by 144
“Thus, hyperphosphorylated tau, including tau phosphorylated at AT8 and PHF1 sites, but not insoluble tau, may cause tau-induced neural dysfunction in the en- torhinal cortex, ultimately leading to impaired place learning and memory.”
BackgroundSelf-citationDown-regulation of WW Domain-containing Oxidoreductase Induces Tau Phosphorylation in Vitro
Sze, C.-I., Su, M., Pugazhenthi, S., Jambal, P., Hsu, L.-J., Heath, J., Schultz, L., & Chang, N.-S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401399200 · Cited by 130
Sun, Y., Guo, Y., Feng, X., Jia, M., Ai, N., Dong, Y., Zheng, Y., Fu, L., Yu, B., Zhang, H., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01749-w · Cited by 122
Progressive neurodegeneration in C. elegans model of tauopathy
Miyasaka, T., Ding, Z., Gengyo-Ando, K., Oue, M., Yamaguchi, H., Mitani, S., & Ihara, Y. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.017 · Cited by 115
“…tau gene into mice, characteristic pathological changes and some clinical features of FTDP-17 were recaptured (Gotz et al., 2001; Ishihara et al., 1999, 2001; Lewis et al., 2000; Lim et al., 2001; Probst et al., 2000; Spittaels et al., 1999; Tanemura et al., 2001, 2002; Tatebayashi et al., 2002).”
BackgroundSelf-citationTau physiology and pathomechanisms in frontotemporal lobar degeneration
Bodea, L., Eckert, A., Ittner, L. M., Piguet, O., & Götz, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13600 · Cited by 104
“1998a), was introduced into the human 2N4R tau backbone and expressed in mice under control of the platelet-derived growth factor b-chain promoter (Tanemura et al. 2001).”
BackgroundMethodZhao, Y., Tseng, I.-C., Heyser, C. J., Rockenstein, E., Mante, M., Adame, A., Zheng, Q., Huang, T., Wang, X., Arslan, P. E., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.08.020 · Cited by 98
“Overexpression of disease-linked tau mutants induces neuronal cell death and behavioral abnormalities in mice (Ikeda et al., 2005; Lewis et al., 2000; Tanemura et al., 2001; Yoshiyama et al., 2007).”
BackgroundTau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration
Sahara, N., Maeda, S., & Takashima, A. (2008) · Current Alzheimer Research · doi:10.2174/156720508786898442 · Cited by 99
Self-citationMediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98
FTDP-17 Tau Mutations Induce Distinct Effects on Aggregation and Microtubule Interactions
Combs, B., & Gamblin, T. C. (2012) · Biochemistry · doi:10.1021/bi3010818 · Cited by 79
“Certain FTDP-17 mutations have been shown to increase the rate or total amount of tau aggregation both in vitro and in vivo which may be leading to earlyonset tauopathies (22, 26, 34, 38, 39); some FTDP-17 mutants show decreased binding to microtubules and an impaired ability to stabilize polymerization of tubulin whi…”
BackgroundROCKENSTEIN, E., CREWS, L., & MASLIAH, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.013 · Cited by 65
Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy
Koller, E. J., Gonzalez De La Cruz, E., Machula, T., Ibanez, K. R., Lin, W.-L., Williams, T., Riffe, C. J., Ryu, D., Strang, K. H., Liu, X., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz151 · Cited by 63
Johnson, G. V. W., & Bailey, C. D. C. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4505 · Cited by 61
Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy
Takashima, A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14403 · Cited by 40
“…that a soluble form of hyperphosphorylated tau (called ADP tau) sequesters normal tau, MAP1, and MAP2 from microtubules, causing the microtubules to collapse [1–4], and with our previous observations that neurons accumulating hyperphosphorylated tau are not immunore-active for tubulin [39,40,42].”
Self-citationSpeicher, A. M., Korn, L., Csatári, J., Gonzalez-Cano, L., Heming, M., Thomas, C., Schroeter, C. B., Schafflick, D., Li, X., Gola, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123476119 · Cited by 28
Metadata
- Authors
- Tanemura, K., Akagi, T., Murayama, M., Kikuchi, N., Murayama, O., Hashikawa, T., Yoshiike, Y., Park, J.-M., Matsuda, K., Nakao, S., Sun, X., Sato, S., Yamaguchi, H., & Takashima, A.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 8
- Issue
- 6
- Pages
- 1036-1045
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2088384294
- Cited by
- 132
- References
- 10
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.